William Blair initiated coverage of Albany Molecular Research (NASDAQ:AMRI) with an “outperform” rating. The stock closed at $17.31 on May 19.Read More
Closely-held CRISPR Therapeutics has appointed Marc Becker as CFO to further support the company’s efforts to develop game-changing drugs derived from its proprietary CRISPR-Cas9 gene-editing technology platform.
Mr. Becker is a seasoned executive who brings more than 20 years of experience in commercial, operational and corporate finance and a deep understanding of the global biopharmaceutical industry.Read More
Rigel Pharmaceuticals (NASDAQ:RIGL) has appointed Dr. Anne-Marie Duliege, as CMO, replacing Dr. Elliott Grossbard, who is retiring after 14 years with the company.
Dr. Grossbard will remain with the company, advising on the NDA filing and regulatory strategy for fostamatinib in immune thrombocytopenic purpura.Read More
Closely-held Soricimed Biopharma has named Bob Cory as VP of business development and appointed Tom Reeves, a director, as chairman.
Dr. Cory has over 20 years of business and corporate development leadership experience in the biopharmaceutical industry. Most recently, he was VP of business development with Qu Biologics. Mr. Reeves currently is president and CEO of closely-held Interface Biologics.Read More